MedCity News October 13, 2023
Pfizer’s new FDA-approved ulcerative colitis drug Velsipity comes from its $6.7 billion Arena Pharmaceuticals acquisition. The small molecule will compete against blockbuster Bristol Myers Squibb drug Zeposia, which addresses the same target.
Ulcerative colitis has several available treatments, including one from Pfizer. FDA approval of a new drug gives Pfizer an opportunity to expand its reach in this market with a molecule whose blockbuster potential could justify the premium price the pharmaceutical giant paid to get it.
The Friday approval of the drug, etrasimod, covers the treatment of moderately to severely active ulcerative colitis in adults. The once-daily pill will be marketed as Velsipity.
Ulcerative colitis, or UC, is a chronic inflammatory bowel disease driven by an excessive immune response....
Today's Sponsors
Today's Sponsor